FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377695786> ?p ?o ?g. }

• W4377695786 endingPage "909" @default.
• W4377695786 startingPage "898" @default.
• W4377695786 abstract "•Body weight management by RYGB surgery has been shown to ameliorate both CVD and NAFLD. •We assessed the hepatic gene expression and plasma metabolite changes in patients after RYGB surgery. •Expression of genes of the alternate BA synthesis and biliary cholesterol elimination pathways are induced after RYGB. •RYGB increases plasma FGF19 and lowers plasma C4 indicating decreased BA synthesis through the classical pathway. •Decreased plasma cholesterol synthesis markers upon RYGB correlate with improved NAFLD histology after surgery. Background & Aims Roux-en-Y gastric bypass (RYGB), the most effective surgical procedure for weight loss, decreases obesity and ameliorates comorbidities, such as non-alcoholic fatty liver (NAFLD) and cardiovascular (CVD) diseases. Cholesterol is a major CVD risk factor and modulator of NAFLD development, and the liver tightly controls its metabolism. How RYGB surgery modulates systemic and hepatic cholesterol metabolism is still unclear. Methods We studied the hepatic transcriptome of 26 patients with obesity but not diabetes before and 1 year after undergoing RYGB. In parallel, we measured quantitative changes in plasma cholesterol metabolites and bile acids (BAs). Results RYGB surgery improved systemic cholesterol metabolism and increased plasma total and primary BA levels. Transcriptomic analysis revealed specific alterations in the liver after RYGB, with the downregulation of a module of genes implicated in inflammation and the upregulation of three modules, one associated with BA metabolism. A dedicated analysis of hepatic genes related to cholesterol homeostasis pointed towards increased biliary cholesterol elimination after RYGB, associated with enhancement of the alternate, but not the classical, BA synthesis pathway. In parallel, alterations in the expression of genes involved in cholesterol uptake and intracellular trafficking indicate improved hepatic free cholesterol handling. Finally, RYGB decreased plasma markers of cholesterol synthesis, which correlated with an improvement in liver disease status after surgery. Conclusions Our results identify specific regulatory effects of RYGB on inflammation and cholesterol metabolism. RYGB alters the hepatic transcriptome signature, likely improving liver cholesterol homeostasis. These gene regulatory effects are reflected by systemic post-surgery changes of cholesterol-related metabolites, corroborating the beneficial effects of RYGB on both hepatic and systemic cholesterol homeostasis. Impact and implications Roux-en-Y gastric bypass (RYGB) is a widely used bariatric surgery procedure with proven efficacy in body weight management, combatting cardiovascular disease (CVD) and non-alcoholic fatty liver disease (NAFLD). RYGB exerts many beneficial metabolic effects, by lowering plasma cholesterol and improving atherogenic dyslipidemia. Using a cohort of patients undergoing RYGB, studied before and 1 year after surgery, we analyzed how RYGB modulates hepatic and systemic cholesterol and bile acid metabolism. The results of our study provide important insights on the regulation of cholesterol homeostasis after RYGB and open avenues that could guide future monitoring and treatment strategies targeting CVD and NAFLD in obesity. Roux-en-Y gastric bypass (RYGB), the most effective surgical procedure for weight loss, decreases obesity and ameliorates comorbidities, such as non-alcoholic fatty liver (NAFLD) and cardiovascular (CVD) diseases. Cholesterol is a major CVD risk factor and modulator of NAFLD development, and the liver tightly controls its metabolism. How RYGB surgery modulates systemic and hepatic cholesterol metabolism is still unclear. We studied the hepatic transcriptome of 26 patients with obesity but not diabetes before and 1 year after undergoing RYGB. In parallel, we measured quantitative changes in plasma cholesterol metabolites and bile acids (BAs). RYGB surgery improved systemic cholesterol metabolism and increased plasma total and primary BA levels. Transcriptomic analysis revealed specific alterations in the liver after RYGB, with the downregulation of a module of genes implicated in inflammation and the upregulation of three modules, one associated with BA metabolism. A dedicated analysis of hepatic genes related to cholesterol homeostasis pointed towards increased biliary cholesterol elimination after RYGB, associated with enhancement of the alternate, but not the classical, BA synthesis pathway. In parallel, alterations in the expression of genes involved in cholesterol uptake and intracellular trafficking indicate improved hepatic free cholesterol handling. Finally, RYGB decreased plasma markers of cholesterol synthesis, which correlated with an improvement in liver disease status after surgery. Our results identify specific regulatory effects of RYGB on inflammation and cholesterol metabolism. RYGB alters the hepatic transcriptome signature, likely improving liver cholesterol homeostasis. These gene regulatory effects are reflected by systemic post-surgery changes of cholesterol-related metabolites, corroborating the beneficial effects of RYGB on both hepatic and systemic cholesterol homeostasis." @default.
• W4377695786 created "2023-05-24" @default.
• W4377695786 creator A5000026424 @default.
• W4377695786 creator A5001127450 @default.
• W4377695786 creator A5001525881 @default.
• W4377695786 creator A5005063608 @default.
• W4377695786 creator A5005521737 @default.
• W4377695786 creator A5008982988 @default.
• W4377695786 creator A5010711280 @default.
• W4377695786 creator A5018906400 @default.
• W4377695786 creator A5023719156 @default.
• W4377695786 creator A5030338756 @default.
• W4377695786 creator A5031245985 @default.
• W4377695786 creator A5036090523 @default.
• W4377695786 creator A5037824940 @default.
• W4377695786 creator A5047135384 @default.
• W4377695786 creator A5048948927 @default.
• W4377695786 creator A5059870179 @default.
• W4377695786 creator A5060220359 @default.
• W4377695786 creator A5065135745 @default.
• W4377695786 creator A5065453844 @default.
• W4377695786 creator A5070970519 @default.
• W4377695786 creator A5084831836 @default.
• W4377695786 creator A5091827744 @default.
• W4377695786 date "2023-10-01" @default.
• W4377695786 modified "2023-10-16" @default.
• W4377695786 title "Roux-en-Y gastric bypass induces hepatic transcriptomic signatures and plasma metabolite changes indicative of improved cholesterol homeostasis" @default.
• W4377695786 cites W1196165627 @default.
• W4377695786 cites W1922826700 @default.
• W4377695786 cites W1966327575 @default.
• W4377695786 cites W1974800489 @default.
• W4377695786 cites W1984345984 @default.
• W4377695786 cites W1986056701 @default.
• W4377695786 cites W1988607926 @default.
• W4377695786 cites W1992969398 @default.
• W4377695786 cites W2007184833 @default.
• W4377695786 cites W2013494570 @default.
• W4377695786 cites W2014756514 @default.
• W4377695786 cites W2021000378 @default.
• W4377695786 cites W2024639496 @default.
• W4377695786 cites W2041297399 @default.
• W4377695786 cites W2042981158 @default.
• W4377695786 cites W2057194981 @default.
• W4377695786 cites W2060287557 @default.
• W4377695786 cites W2062412540 @default.
• W4377695786 cites W2067740038 @default.
• W4377695786 cites W2083782159 @default.
• W4377695786 cites W2090492013 @default.
• W4377695786 cites W2106515170 @default.
• W4377695786 cites W2116858703 @default.
• W4377695786 cites W2124260053 @default.
• W4377695786 cites W2125239733 @default.
• W4377695786 cites W2126949934 @default.
• W4377695786 cites W2138486337 @default.
• W4377695786 cites W2139776835 @default.
• W4377695786 cites W2153014921 @default.
• W4377695786 cites W2156356963 @default.
• W4377695786 cites W2162561439 @default.
• W4377695786 cites W2171697576 @default.
• W4377695786 cites W2279325731 @default.
• W4377695786 cites W2330772909 @default.
• W4377695786 cites W2396784827 @default.
• W4377695786 cites W2471434980 @default.
• W4377695786 cites W2581434358 @default.
• W4377695786 cites W2591920149 @default.
• W4377695786 cites W2611140688 @default.
• W4377695786 cites W2625485505 @default.
• W4377695786 cites W2735896722 @default.
• W4377695786 cites W2742973807 @default.
• W4377695786 cites W2808516166 @default.
• W4377695786 cites W2905460453 @default.
• W4377695786 cites W2910703652 @default.
• W4377695786 cites W2914025298 @default.
• W4377695786 cites W2915948028 @default.
• W4377695786 cites W2917520831 @default.
• W4377695786 cites W2923741290 @default.
• W4377695786 cites W2946300595 @default.
• W4377695786 cites W2951755083 @default.
• W4377695786 cites W2959069720 @default.
• W4377695786 cites W3004610618 @default.
• W4377695786 cites W3011341999 @default.
• W4377695786 cites W3019814646 @default.
• W4377695786 cites W3034346518 @default.
• W4377695786 cites W3042596489 @default.
• W4377695786 cites W3113529260 @default.
• W4377695786 cites W3169209367 @default.
• W4377695786 cites W3208419840 @default.
• W4377695786 cites W3208660753 @default.
• W4377695786 cites W356196484 @default.
• W4377695786 cites W4280622190 @default.
• W4377695786 cites W4293201222 @default.
• W4377695786 cites W774501851 @default.
• W4377695786 doi "https://doi.org/10.1016/j.jhep.2023.05.012" @default.
• W4377695786 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37230231" @default.
• W4377695786 hasPublicationYear "2023" @default.
• W4377695786 type Work @default.
• W4377695786 citedByCount "0" @default.
• W4377695786 crossrefType "journal-article" @default.

• next